MarketVIEW Endemic Vaccines

Lyme Borreliosis
Vaccines Forecast

North American demand model - Complete (October 2026) European analysis - In preparation

Lyme borreliosis is caused by infection with Borrelia burgdorferi sensu lato spirochete bacteria, transmitted to humans through the bite of infected Ixodes ticks, Ixodes scapularis and I. pacificus in North America, I. ricinus across Europe. Disease ranges from the classic erythema migrans rash through to disseminated neuroborreliosis, Lyme arthritis and cardiac involvement if left untreated. GSK's OspA-based LYMErix, the field's only previously licensed vaccine, was withdrawn in 2002 amid poor sales and an unresolved autoimmune-arthritis controversy. Valneva and Pfizer's next-generation candidate, PF-07307405 (formerly VLA15), narrowly missed the primary endpoint of its pivotal Phase 3 VALOR trial in March 2026, but demonstrated 73-75% efficacy against confirmed Lyme disease, and its EU marketing authorisation application was validated by the EMA on 14 August 2026, formally starting European review, a genuine field-defining moment after more than two decades without a route back to market.

476,000 US Cases Estimated Annually VALOR: 74% Efficacy, Endpoint Narrowly Missed Tick Range Expanding ~46km/Year North Only Vaccine Ever Licensed, Withdrawn 2002 EU MAA Validated by EMA, August 2026 VALOR Data Presented at IDWeek 2026
Product catalogue
VAMV024
North American model - October 2026

Product code
VAMV024
North American demand model
Complete - October 2026
European analysis
Pending - scope and timing set with clients
Format
Executive presentation and Excel model, per region
Geography
United States and Canada, with sub-state resolution in the US (complete); Europe (in preparation)
Populations
Ages 5 and over; paediatric and adult
Forecast horizon
North America: launch to 2045
Scenarios
Four recommendation scenarios, plus a competing-intervention overlay and sensitivity testing
Pricing
Multiple price cases, converted to net revenue through detailed payer-mix inputs
Availability
Syndicated or bespoke
476,000
Americans diagnosed & treated for
Lyme disease each year (CDC estimate)
132,000
Lyme borreliosis cases reported to
national surveillance across Europe/yr
74%
Efficacy shown by PF-07307405 in Phase 3
VALOR, primary endpoint narrowly missed
2002
Year LYMErix, the only previously
licensed Lyme vaccine, was withdrawn
Disease background

A rapidly expanding vector-borne disease, now on the cusp of its first vaccine in over two decades

This review sets out Borrelia biology and Ixodes tick transmission, the clinical spectrum of Lyme borreliosis, and the latest epidemiological evidence for a disease whose range and incidence are both expanding, before turning to a vaccine pipeline that has now delivered its first pivotal Phase 3 efficacy readout since LYMErix.

CDC/ECDC 2023-2025 data, March 2026 VALOR results & August 2026 EU filing

Pathogen overview - Borrelia burgdorferi sensu lato & Ixodes ticks

Lyme borreliosis (Lyme disease) is caused by infection with spirochete bacteria of the Borrelia burgdorferi sensu lato species complex, principally B. burgdorferi sensu stricto in North America and B. afzelii and B. garinii in Europe and Asia. The pathogen is transmitted to humans through the bite of infected Ixodes ticks: Ixodes scapularis (the blacklegged tick) across the eastern and upper midwestern United States, Ixodes pacificus along the US Pacific coast, and Ixodes ricinus across most of Europe. Ticks typically require an extended attachment period, often 36 to 48 hours or more, to transmit sufficient spirochetes, which is why prompt tick checks and removal remain a core, if imperfect, prevention message alongside any future vaccine.

Clinical presentation spans a wide spectrum. Most infections begin with erythema migrans (EM), an expanding, often but not always target-shaped skin rash at the bite site, typically accompanied by fatigue, headache and low-grade fever, and generally treatable with a course of oral antibiotics if caught early. Left untreated, or in a minority of treated cases, infection can disseminate to cause neuroborreliosis (facial palsy, meningitis, radiculoneuritis), Lyme arthritis (typically a recurring, swollen knee), cardiac involvement (Lyme carditis, including atrioventricular block) and, in a subset of patients, post-treatment Lyme disease syndrome, a poorly understood, persistent constellation of fatigue, pain and cognitive symptoms that remains a source of significant patient burden and clinical debate.

Reported case counts substantially understate the true US burden. CDC surveillance recorded just over 89,000 reported Lyme disease cases in 2023, yet the agency's own analysis of commercial insurance claims data estimates that approximately 476,000 people are actually diagnosed and treated for Lyme disease in the United States each year, a figure roughly five times higher than passive surveillance alone would suggest, reflecting significant underreporting and underdiagnosis rather than a change in the underlying case definition. Across the EU/EEA, an average of nearly 132,000 Lyme borreliosis cases are reported to national surveillance systems annually, and an estimated 30% of the European population lives in areas of high incidence (10 or more cases per 100,000 population per year), though country-level reporting practices vary widely and comparability across the EU/EEA remains limited.

The prevailing scientific consensus links rising Lyme incidence substantially to climate-driven range expansion of the Ixodes vector. Ixodes scapularis populations have been expanding northward into Canada at a modelled rate of approximately 46 km per year, with climate projections suggesting the tick's theoretically suitable range could shift northward by around 200 km by the 2020s and as much as 1,000 km by the 2080s under high-emissions scenarios. Milder winters and longer tick-activity seasons are producing similar, if less precisely quantified, range and seasonality shifts across the European I. ricinus belt, a structural growth driver this report's demand model is built to capture.

2026 476,000 US cases/yr estimated (CDC) vs 89,000 reported  |  ~132,000 EU cases/yr reported (ECDC)  |  I. scapularis range expanding ~46km/yr north  |  PF-07307405 (VLA15) Phase 3 VALOR: 73-75% efficacy, primary endpoint narrowly missed, EU MAA validated by EMA Aug 2026
Product & competitor landscape

From a withdrawn 1990s vaccine to a pivotal Phase 3 readout, twenty-four years apart

Lyme vaccine development has a long, difficult history, shaped by one licensed product's commercial withdrawal and a theoretical autoimmune safety concern that was never substantiated. Valneva and Pfizer's PF-07307405 has now become the field's first candidate since LYMErix to report pivotal efficacy data, and although VALOR narrowly missed its formal statistical success criterion, the efficacy observed has been sufficient for the partners to take the programme forward on the totality of the clinical evidence.

  • GSK (SmithKline Beecham)Withdrawn 2002, historical
    LYMErix OspA recombinant, monovalent
    Licensed by the FDA in December 1998, the field's only previously approved Lyme vaccine was withdrawn from the market in February 2002 by GlaxoSmithKline, citing poor sales after negative publicity and litigation over a theoretical, and ultimately unsubstantiated, link to autoimmune arthritis. An FDA advisory panel had unanimously supported its licensure, and post-marketing VAERS data showed no unusual signal.
  • Valneva / PfizerEndpoint narrowly missed, EU MAA under EMA review
    PF-07307405 (formerly VLA15, LB6V) 6-valent OspA, protein subunit
    Pfizer and Valneva announced on 23 March 2026 that PF-07307405 narrowly missed the primary endpoint of the pivotal Phase 3 VALOR trial, conducted across 9,437 participants aged 5 and older in the United States, Canada and Europe. The primary analysis, from 28 days after dose 4 in season 2, showed 73.2% vaccine efficacy against confirmed Lyme disease, but the lower bound of the 95% confidence interval (15.8-93.5%) fell below the pre-specified 20% success threshold, an outcome driven principally by case under-accrual after enrolment was reduced from approximately 18,000 to 9,437 participants following quality-control issues at a third-party clinical site operator. The supportive analysis from 1 day post-dose 4 showed 74.8% efficacy (95% CI 21.7-93.9%), clearing the same threshold. The candidate was well tolerated with no safety concerns identified. On the totality of the clinical evidence, the partners have taken the programme into regulatory review. On 14 August 2026 Pfizer and Valneva confirmed that the EU marketing authorisation application had been validated by the European Medicines Agency, which has begun its assessment; the submission, based on the more than 70% efficacy observed in VALOR, seeks an indication in individuals aged five years and older, and the programme carries EMA PRIME designation. A US BLA submission (FDA Fast Track) is expected in the second half of 2026. Valneva has guided that regulatory decisions are anticipated within twelve months, leaving potential launch as early as 2027. Pfizer and Valneva also presented data from the VALOR study at IDWeek 2026 in October 2026.
  • ModernaPhase I/II, dose-ranging
    mRNA-1982 & mRNA-1975 mRNA-LNP, mono- & tetravalent
    Moderna's first bacterial-target mRNA candidates for Lyme disease, mRNA-1982 (targeting the dominant US-relevant Borrelia species) and mRNA-1975 (targeting four major US and European Borrelia species), remain in an ongoing Phase 1/2, placebo-controlled, dose-ranging trial in healthy adults. Interim safety and immunogenicity results were published in January 2026 and describe an acceptable safety profile and favourable early immune responses.
  • Tonix Pharmaceuticals / UMass Chan (MassBiologics)Phase I complete, monoclonal antibody
    TNX-4800 (Lyme PrEP) Long-acting borreliacidal monoclonal antibody
    A complementary, non-vaccine approach: this human monoclonal antibody, designed for seasonal pre-exposure prophylaxis by neutralising Borrelia within the tick midgut before transmission, completed a Phase I safety and pharmacokinetics study in 2026, with an adaptive Phase 2 field study expected in the first half of 2027.
  • Baxter & Sanofi Pasteur (historical)Discontinued, historical
    Earlier OspA-based programmes
    Baxter reported promising Phase I/II data for its own OspA-based candidate in 2013 before selling its vaccine portfolio to Shire, which chose not to progress it further. Sanofi Pasteur's predecessor, Pasteur Merieux Connaught, also explored an OspA approach in the 1990s alongside SmithKline Beecham, but did not bring a product to market.
Field inflection point
74% efficacy

Twenty-four years after LYMErix left the market, Valneva and Pfizer's PF-07307405 has become the first Lyme disease vaccine candidate to report pivotal Phase 3 efficacy data. VALOR narrowly missed its formal statistical success criterion, on the confidence interval rather than the point estimate, but a 73-75% efficacy result across 9,437 participants, coupled with a favourable safety profile, coverage from age 5 upward and an EU marketing authorisation application now validated and under EMA assessment, materially de-risks the category just as Moderna's mRNA candidates progress through early clinical testing and a monoclonal antibody alternative advances toward field testing. It arrives against a backdrop of significant, and likely still-understated, US burden, a widening European and North American endemic range, and renewed public and clinical urgency around tick-borne disease prevention. The VacZine Analytics model quantifies the commercial opportunity this creates across 27 major Western markets under LO, BASE and HI pricing scenarios.

Regional analyses

Two regional analyses, one proposition

Lyme disease risk is intensely local, and so is demand for a Lyme vaccine. VacZine has therefore built separate, purpose-designed analyses for North America and Europe rather than one generic forecast.

Status: Complete (October 2026)

North America - United States and Canada

A ground-up demand model for the first Lyme vaccine candidate in late-stage development, forecasting doses and net revenue from launch to 2045.

  • Multiple exposure pools. Demand is built from the people who are genuinely at risk, not from headline population counts.
  • Sub-state resolution. Lyme risk is not uniform within a state, and neither is the model.
  • Four recommendation scenarios. The full range of policy outcomes the vaccine could face, each with its own demand trajectory.
  • Traveller components. Demand that a purely local view of the market would miss.
  • Competing-intervention overlay. Tests how an alternative prevention option could dampen vaccine uptake.
  • Layered payer mix and pricing. Multiple price cases, converted into realistic net revenue across a detailed payer landscape.
  • Course and booster dynamics. Volume reflects the full dosing schedule, not first doses alone.
  • Fully documented. Every input is sourced or stated as an assumption, with sensitivity testing across the key drivers.

Delivered as an executive presentation with a client-ready Excel model. Request a briefing to see how the scenarios play out.

Request a briefing →
Status: In preparation

Europe

A separate European demand analysis is being scoped. Country coverage, depth and timing will be shaped with clients, so early conversations directly influence what is built.

Register your interest to be part of that conversation.

Register your interest →
Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report, spanning disease burden, target product profile design, the R&D competitive landscape and scenario-based demand forecasting, delivered as separate regional analyses.

Regional demand forecasts

North America (complete, October 2026); Europe (in preparation).

Competitor & pipeline review

Full review of PF-07307405 (VLA15), Moderna's mRNA-1982/1975, the TNX-4800 monoclonal antibody approach and the LYMErix withdrawal precedent.

Target product profile design

Ideal target product profile assessment across adult and paediatric populations, informed by the VALOR trial's own age-5-and-up coverage.

LO/BASE/HI scenario forecasts

Three-scenario pricing and revenue forecasts to 2040, reflecting PF-07307405's pipeline progression and alternative uptake assumptions.

Disease burden & epidemiology

Full epidemiological review across US and European Lyme borreliosis burden, including CDC's claims-based estimate and the climate-driven expansion of tick range.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in Lyme vaccine investment, market entry and access planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the indication and geography framework. Full volume/value outputs and pricing assumptions are in the licensed model.

Indication / segmentGeographyTarget groupVaccine statusRevenue scenario
Lyme disease prevention - generalUnited States & CanadaAdult, general populationPre-licensure (EU MAA under review)Modelled
Lyme disease prevention - paediatricUnited States & CanadaChildren aged 5 and abovePre-licensure (EU MAA under review)Modelled
Lyme disease prevention - EuropeEuropeAdult & paediatricPre-licensureIn preparation
North America - 2027-2045 net revenue by recommendation scenario[Licensed][Licensed][Licensed][Licensed]
█████████████████████████[Licensed]
Full model in the licensed workbook
North America complete (October 2026) - Europe in preparation - all Lyme borreliosis indications
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Lyme borreliosis vaccine opportunity, with a regional analysis for North America and for Europe.

  • Executive presentation (PDF) - refreshed from the original 197-slide edition, covering disease background, epidemiology, target product profile, clinical development issues and full competitive landscape review
  • MS-Excel value/volume forecast model - refreshed from the original 75+ worksheet edition, with demand outputs across all relevant indications and target groups, per region
  • LO/BASE/HI pricing scenario framework - three-scenario revenue modelling reflecting alternative pipeline and uptake outcomes
  • Competitor intelligence - PF-07307405 (VLA15), Moderna's mRNA-1982/1975, TNX-4800 and the LYMErix withdrawal precedent
  • Updated epidemiology module - CDC claims-based burden estimates, ECDC surveillance data and climate-driven tick range expansion evidence
  • North American demand model and write-up - complete (October 2026)
  • European analysis - in preparation; scope agreed with clients
  • Early decision-making support - target product profile and market entry strategy guidance for Lyme vaccine planning
Target audience

Built for organisations evaluating the Lyme borreliosis vaccine opportunity

Most valuable to teams assessing the Lyme disease vaccine market against their own pipeline, BD ambitions or investment thesis, drawing on VacZine Analytics' long standing expertise in travel diseases.

Vaccine developers

Positioning, target product profile and commercial feasibility assessment for Lyme candidates at any pipeline stage.

Corporate strategy & BD

Validate the size and structure of a market moving from zero to one credible late-stage candidate, now that PF-07307405 has completed Phase 3 and entered EU regulatory review.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on Valneva/Pfizer, Moderna and the wider Lyme and travel vaccine field.

Public health & immunisation programmes

Demand modelling to support future endemic-region immunisation programme planning across at-risk adult and paediatric populations.

Researchers & academia

Comprehensive epidemiology and R&D landscape review to support grant, translational and tick-borne disease prevention planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public and private channels in North American and European endemic markets.

About this analysis · VAMV024

VacZine Analytics has long standing expertise in travel diseases, positioning us to track the Lyme borreliosis vaccine market's decades-long, difficult supply side against its faster-moving epidemiological and pipeline trend. This is a genuinely comprehensive analysis, spanning both North American and European Lyme borreliosis burden, and it has been well received by clients in the field for the depth of its target product profile and clinical development review. Few groups have followed this historically fraught market as closely for as long, and that recognised, independent expertise underpins everything in the analysis.

This analysis was updated in August 2026, covering the travel component, to incorporate current US and European burden data, the climate-driven expansion of Ixodes tick range, and Valneva/Pfizer's PF-07307405 (formerly VLA15), the first Lyme vaccine candidate to report pivotal Phase 3 efficacy data since LYMErix, notwithstanding VALOR's narrow miss on its primary endpoint, and now the first to enter European regulatory review, its EU marketing authorisation application having been validated by the EMA on 14 August 2026. In October 2026 VacZine completed a new North American demand model, built from the ground up following the Phase 3 VALOR results; a European analysis is in preparation. Where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV024 · Syndicated & bespoke

The North American model is ready now

The North American model is ready now. Book a briefing to walk through the scenarios, or register your interest in the European analysis to help shape its scope.